Table 2 Studies of imatinib in newly... | American Society of Hematology

Table 2

Studies of imatinib in newly diagnosed Ph⁺ ALL

Author, year	Study group	Study name	N	Dose	CR (%)	BMT rate (%)	Overall survival
Adults
Thomas et al, 2004²²	MD Anderson	N/A	20	400 mg (600 mg in maintenance)	93	50	75% at 20 mo
Yanada et al, 2006²⁶	JALSG	ALL202Ph⁺	80	600 mg	96	61	75% at 1 y
Wassmann et al, 2006²⁰	GMALL	N/A	92	400-600 mg	95	77	36% (alternating schedule), 43% (concurrent schedule) at 2 y
de Labarthe et al, 2007²³	GRAALL	GRAAPH-2003	45	600 mg	96	48	65% at 18 mo
Ribera et al, 2010²⁵	PETHEMA	CSTIBES02	30	400 mg	90	70	30% at 4 y
Bassan et al, 2010²⁷	NILG	09/00	59	600 mg	92	63	38% at 5 y
Older adults
Vignetti et al, 2007²⁴	GIMEMA	LAL0201-B	30	800 mg	100	N/A	74% at 12 mo
Ottmann et al, 2007³²	GMALL	N/A	55	600 mg	96 (imatinib), 50 (chemo)	N/A	42% at 24 mo
Children
Schultz et al, 2009³⁶	COG	AALL0031	92	340 mg/m²	Not stated	N/A*	80% (EFS) at 3 y
Ongoing studies
N/A	UK NCRI, ECOG	UKALLXII/ECOG2993	175	600 mg	95	Awaited	Awaited
N/A	GRAALL	GRAAPH-2COG05	188	800 mg	100 (imatinib DIV), 96 (imatinib hyperCVAD)	62	62% at 2 y

Author, year	Study group	Study name	N	Dose	CR (%)	BMT rate (%)	Overall survival
Adults
Thomas et al, 2004²²	MD Anderson	N/A	20	400 mg (600 mg in maintenance)	93	50	75% at 20 mo
Yanada et al, 2006²⁶	JALSG	ALL202Ph⁺	80	600 mg	96	61	75% at 1 y
Wassmann et al, 2006²⁰	GMALL	N/A	92	400-600 mg	95	77	36% (alternating schedule), 43% (concurrent schedule) at 2 y
de Labarthe et al, 2007²³	GRAALL	GRAAPH-2003	45	600 mg	96	48	65% at 18 mo
Ribera et al, 2010²⁵	PETHEMA	CSTIBES02	30	400 mg	90	70	30% at 4 y
Bassan et al, 2010²⁷	NILG	09/00	59	600 mg	92	63	38% at 5 y
Older adults
Vignetti et al, 2007²⁴	GIMEMA	LAL0201-B	30	800 mg	100	N/A	74% at 12 mo
Ottmann et al, 2007³²	GMALL	N/A	55	600 mg	96 (imatinib), 50 (chemo)	N/A	42% at 24 mo
Children
Schultz et al, 2009³⁶	COG	AALL0031	92	340 mg/m²	Not stated	N/A*	80% (EFS) at 3 y
Ongoing studies
N/A	UK NCRI, ECOG	UKALLXII/ECOG2993	175	600 mg	95	Awaited	Awaited
N/A	GRAALL	GRAAPH-2COG05	188	800 mg	100 (imatinib DIV), 96 (imatinib hyperCVAD)	62	62% at 2 y

Only patients with sibling donors were eligible for transplant.

n = 83 evaluable.

BMT indicates bone marrow transplantation; CR, complete remission; DIV, High-dose imatinib mesylate combined with vincristine and dexamethasone; EFS, event-free survival; Ph⁺ ALL, Philadelphia chromosome–positive acute lymphoblastic leukemia; and N/A, not applicable.

View Large

This Feature Is Available To Subscribers Only